biostudies-literatureUnknown5(1)van Rensburg IC<h4>Introduction</h4>Studies show that B-cells, in addition to producing antibodies and antigen-presentation, are able to produce cytokines as well. These include regulatory cytokines such as IL-10 by regulatory B-cells. Furthermore, a rare regulatory subset of B-cells have the potential to express FasL, which is a death-inducing ligand. This subset of B-cells have a positive role during autoimmune disease, but has not yet been studied during tuberculosis. These FasL-expressing B-cells are induced by bacterial LPS and CpG, thus we hypothesized that this phenotype might be induced during tuberculosis as well.<h4>Methods</h4>B-cells from participants with TB (at diagnosis and during treatment) and controls were collected, and analyzed by means of real-time PCR and flow cytometry. In additionImmunity, inflammation and disease57-67https://www.ebi.ac.uk/biostudies/studies/S-EPMC5322165biostudies-literatureB-cells with a FasL expressing regulatory phenotype are induced following successful anti-tuberculosis treatment.PMC5322165Walzl GLoxton AGKleynhans Lvan Rensburg ICKeyser AfalseB-cells with a FasL expressing regulatory phenotype are induced following successful anti-tuberculosis treatment.<h4>Introduction</h4>Studies show that B-cells, in addition to producing antibodies and antigen-presentation, are able to produce cytokines as well. These include regulatory cytokines such as IL-10 by regulatory B-cells. Furthermore, a rare regulatory subset of B-cells have the potential to express FasL, which is a death-inducing ligand. This subset of B-cells have a positive role during autoimmune disease, but has not yet been studied during tuberculosis. These FasL-expressing B-cells are induced by bacterial LPS and CpG, thus we hypothesized that this phenotype might be induced during tuberculosis as well.<h4>Methods</h4>B-cells from participants with TB (at diagnosis and during treatment) and controls were collected, and analyzed by means of real-time PCR and flow cytometry. In addition2017-01-01T00:00:00Z2017 Mar2025-04-18T19:23:13.623Z2019-03-26T23:41:24ZS-EPMC53221652825092510.1002/iid3.140